Securities Act of 1933, as amended, and Section 21E of the U.S. Ĭertain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. As of December 31, 2022, QIAGEN employed approximately 6,200 people in over 35 locations worldwide.

QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare), Applied Testing (primarily forensics), Pharma (pharma and biotech companies) and Academia (life sciences research). Automation solutions tie these together in seamless and cost-effective workflows. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights.

Assay technologies make these biomolecules visible and ready for analysis. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. To obtain a printed copy of the 2022 Annual Report please use our contact form or send an email to QIAGEN QIAGEN will provide printed copies of the 2022 Annual Report to shareholders free of charge upon request. The document can be accessed on QIAGEN’s website here. (NYSE: QGEN Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended December 31, 2022, with the U.S. SYBR Green- or Dye-Based One-Step qRT-PCR.Reverse Transcription & cDNA Synthesis for qPCR.Tagged Protein Expression, Purification, Detection.

Directx software development kit